Business
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies
About this update from Agenus Inc.
[{"type":"text","content":"Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, MSS-colorectal, and pancreatic cancersAGEN1571, a novel program targeting tumor-associated macrophages, is entering clinical development in 20226 clinical-stage programs are advancing through strategic partnerships; $220M in upfront and achieved milestone payments received in 2021Cell therapy subsidiary, MiNK Therapeutics (NASDAQ: INKT), launched via an IPO; clinical programs underway in solid tumors and multiple myelomaAdjuvant subsidiary, SaponiQx, has developed a plant cell culture manufacturing process expected to generate GMP grade QS-21 STIMULON™ adjuvant by year end to enable partner clinical studies LEXINGTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the fourth quarter and full year 2021. “We made several important advancements in 2021,” said Garo Armen, PhD, Chief Executive Officer of Agenus. “Our Phase 1 data presentation at SITC demonstrated the best-in-class potential of our flagship program, botensilimab, consistent with its Fc-enhanced design. We partnered our Fc-enhanced TIGIT bispecific with BMS to accelerate its development in high priority indications such as NSCLC. This year, we expect to launch several new botensilimab studies to unlock its franchise potential. In parallel, our R&D team continues to advance novel discoveries, with our macrophage targeting program expected to enter the clinic this year.” Botensilimab is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, colorectal, and pancreatic cancers Phase 1 data from >100 patients treated with botensilimab, as monotherapy or in combination with our PD-1 antibody, balstilimab, presented at SITC.Based on these data, Agenus plans to commence Phase 2 trials in melanoma, MSS-colorectal, and pancreatic cancers in order to: Demonstrate superiority to ipilimumab, which has been approved and extensively studied in melanoma; new melanoma response ...